[go: up one dir, main page]

WO2008048648A3 - Cb1-modulating compounds and their use - Google Patents

Cb1-modulating compounds and their use Download PDF

Info

Publication number
WO2008048648A3
WO2008048648A3 PCT/US2007/022183 US2007022183W WO2008048648A3 WO 2008048648 A3 WO2008048648 A3 WO 2008048648A3 US 2007022183 W US2007022183 W US 2007022183W WO 2008048648 A3 WO2008048648 A3 WO 2008048648A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
disclosed
modulating compounds
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/022183
Other languages
French (fr)
Other versions
WO2008048648A2 (en
Inventor
Roger Olsson
Anne Bulow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of WO2008048648A2 publication Critical patent/WO2008048648A2/en
Publication of WO2008048648A3 publication Critical patent/WO2008048648A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Disclosed herein is a compound of Formula (I). Also disclosed herein is a method of modulating the activity of a cannabinoid receptor using a compound of Formula (I). Furthermore, disclosed herein is a method of treating a disease or condition that would be alleviated, improved or prevented by administration of a compound that modulates a cannabinoid receptor comprising identifying a subject in need thereof and administering to said subject a therapeutically effective amount of a compound of Formula (I). Also disclosed herein are pharmaceutical compositions comprising a compound of Formula (I).
PCT/US2007/022183 2006-10-17 2007-10-17 Cb1-modulating compounds and their use Ceased WO2008048648A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85257906P 2006-10-17 2006-10-17
US60/852,579 2006-10-17

Publications (2)

Publication Number Publication Date
WO2008048648A2 WO2008048648A2 (en) 2008-04-24
WO2008048648A3 true WO2008048648A3 (en) 2008-06-12

Family

ID=39204737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022183 Ceased WO2008048648A2 (en) 2006-10-17 2007-10-17 Cb1-modulating compounds and their use

Country Status (1)

Country Link
WO (1) WO2008048648A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
JP5303561B2 (en) * 2008-08-12 2013-10-02 日本曹達株式会社 Nitrogen-containing heterocyclic derivatives and agricultural and horticultural fungicides
WO2011037128A1 (en) 2009-09-28 2011-03-31 日本曹達株式会社 Nitrogen-containing heterocyclic compound and salt thereof, and bactericide for agricultural and horticultural use
CN102807574B (en) * 2011-05-30 2015-09-02 长春吉大天元化学技术股份有限公司 New pyridine sulphur nitrogen seven-membered ring derivative as antitumor drug, and its preparation method and application
TWI694086B (en) 2014-03-27 2020-05-21 美商銳意公司 Antibodies that bind human cannabinoid 1 (cb1) receptor
JP6668362B2 (en) 2015-02-02 2020-03-18 フォーマ セラピューティクス，インコーポレイテッド 3-Alkyl-4-amide-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
RU2727018C1 (en) 2015-09-30 2020-07-17 Берд Рок Байо, Инк. Antibodies capable of binding to human cannabinoid receptor 1 (cb1)
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044822A1 (en) * 2003-11-07 2005-05-19 Pfizer Products Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044822A1 (en) * 2003-11-07 2005-05-19 Pfizer Products Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOWLETT A C ET AL: "Cannabinoid physiology and pharmacology: 30 years of progress", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 47, 2004, pages 345 - 358, XP004612197, ISSN: 0028-3908 *

Also Published As

Publication number Publication date
WO2008048648A2 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
WO2008048648A3 (en) Cb1-modulating compounds and their use
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
EA021275B9 (en) Heterocyclic compounds, pharmaceutical composition comprising same and use thereof for treatment of pask-mediated disease
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
UA107578C2 (en) COMBINED DIABETES THERAPY
WO2007038669A3 (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
WO2010114824A8 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
PT2150530E (en) Substituted sulfonamide derivatives
EA201200968A1 (en) USE OF TRANS-CLOMIPHENE FOR THE PREVENTION OR TREATMENT OF DIABETES TYPE 2 IN MEN
GB0722077D0 (en) Compounds
WO2008043544A8 (en) Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MX2012014934A (en) Cyclohexyl-azetidinyl antagonists of ccr2.
MX2007004765A (en) Thrombopoietin activity modulating compounds and methods.
WO2008074833A3 (en) Compounds
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
WO2010123959A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
TNSN08506A1 (en) Substituted carboxamides
WO2007128564A3 (en) Use of a compound with rankl activity
WO2006124413A3 (en) Methods for treating drug resistant cancer
WO2007098967A3 (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor
TW200800993A (en) Organic compounds
MX2010014441A (en) Diaryl ureas for treating heart failure.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07839649

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07839649

Country of ref document: EP

Kind code of ref document: A2